Bosutinib

ApprovedTerminated

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Previously Treated PH + CML

Conditions

Previously Treated PH + CML

Trial Timeline

Nov 7, 2014 → Oct 13, 2020

NCT ID

NCT02228382

About Bosutinib

Bosutinib is a approved stage product being developed by Pfizer for Previously Treated PH + CML. The current trial status is terminated. This product is registered under clinical trial identifier NCT02228382. Target conditions include Previously Treated PH + CML.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05363488	Pre-clinical	Completed	Oct 8, 2021	Oct 8, 2021	Myeloid Leukemia
NCT04258943	Phase 1/2	Active	Jul 6, 2020	Jul 1, 2028	Philadelphia Chromosome Positive CML
NCT03128411	Phase 2	Completed	May 15, 2017	Mar 4, 2021	Leukemia, Chronic Myelogenous
NCT02906696	Phase 2	Terminated	Oct 28, 2016	Aug 8, 2019	Blasts Under 15 Percent of Bone Marrow Nucleated Cells
NCT02921477	Phase 1	UNKNOWN	Sep 1, 2016	Dec 31, 2025	Mild Cognitive Impairment
NCT02546375	Pre-clinical	Completed	Jul 15, 2015	Jan 16, 2017	Chronic Myeloid Leukaemia
NCT02501330	Pre-clinical	Completed	Jul 1, 2015	Feb 28, 2024	Chronic Myelogenous Leukemia
NCT02228382	Approved	Terminated	Nov 7, 2014	Oct 13, 2020	Previously Treated PH + CML
NCT01903733	Pre-clinical	Completed	Aug 28, 2013	Jun 5, 2020	Chronic Myeloid Leukemia
NCT01331291	Phase 2	Completed	Apr 1, 2011	Dec 1, 2014	Glioblastoma
NCT00759837	Phase 1	Completed	Oct 1, 2008	May 1, 2009	Breast Cancer
NCT00725426	Phase 1	Completed	Jul 1, 2008	Aug 1, 2008	Healthy
NCT00261846	Phase 2	Completed	Jan 18, 2006	Aug 6, 2015	Chronic Myeloid Leukemia

Competing Products

8 competing products in Previously Treated PH + CML

See all competitors

Product	Company	Stage	Hype Score
SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811	Jiangsu Hengrui Medicine	Phase 3	77
AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim	AstraZeneca	Phase 2	52
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
CRS-207 + CRS-207 + nivolumab + GVAX + CY	Bristol Myers Squibb	Phase 2	51
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Oxaliplatin	Sanofi	Phase 2	51

Other Products from Pfizer